{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:10:02Z","timestamp":1768831802113,"version":"3.49.0"},"reference-count":27,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Education in Japan","award":["23592256"],"award-info":[{"award-number":["23592256"]}]},{"name":"the SENSHIN Medical Research Foundation Grant 2020","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2021,12,13]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Sudden cardiac death (SCD) is the major cause of death in cardiac sarcoidosis (CS). We aimed to identify the prognostic markers for sustained ventricular tachycardia (sVT) and SCD in patients with CS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a prospective observational cohort study for patients with CS diagnosed according to the Japanese or Heart Rhythm Society guidelines between June 2008 and March 2020 in our hospital. The primary endpoint was a composite of the first sVT and SCD. The levels of urinary 8-hydroxy-2\u2032-deoxyguanosine (U-8-OHdG), a marker of oxidative DNA damage that reflects the inflammatory activity of CS, other biomarkers, and indices of cardiac function and renal function were measured on admission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-nine consecutive patients with CS were enrolled; 28 patients with no abnormal <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose (<jats:sup>18<\/jats:sup>F-FDG) accumulation in the heart were excluded and 61 patients with abnormal <jats:sup>18<\/jats:sup>F-FDG accumulation were followed up for a median of 46 months (IQR: 20\u201384). During the follow-up period, 15 of 61 patients showed sVT (n=12) or SCD (n=3). A Cox proportional hazard model showed that U-8-OHdG concentration and presence of ventricular aneurysm (VA) were independent predictors of first sVT\/SCD. The cut-off U-8-OHdG concentration for predicting first sVT\/SCD was 14.9 ng\/mg\u00b7Cr. Patients with U-8-OHdG concentration \u226514.9 ng\/mg\u00b7Cr and VA showed a significantly increased risk of sVT\/SCD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>U-8-OHdG and presence of VA were powerful predictors of first sVT\/SCD in patients with CS, facilitating the stratification of cardiac events and providing relevant information about the substrates of ventricular tachycardia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2021-320244","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T13:20:20Z","timestamp":1643116820000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced oxidative stress and presence of ventricular aneurysm for risk prediction in cardiac sarcoidosis"],"prefix":"10.1136","volume":"108","author":[{"given":"Ryosuke","family":"Yoshitomi","sequence":"first","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-2999","authenticated-orcid":false,"given":"Shigeki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutake","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Nanno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ishiguchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Yoshiga","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Radiology, St Hill Hospital, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reo","family":"Kawano","sequence":"additional","affiliation":[{"name":"Clinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2025091923515252000_108.6.429.1","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/eurheartj\/ehz428","article-title":"Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries","volume":"40","author":"Ekstr\u00f6m","year":"2019","journal-title":"Eur Heart J"},{"key":"2025091923515252000_108.6.429.2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjcard.2021.04.039","article-title":"Long-Term prognostic significance of ventricular repolarization dispersion in patients with cardiac sarcoidosis","volume":"152","author":"Kobayashi","year":"2021","journal-title":"Am J Cardiol"},{"key":"2025091923515252000_108.6.429.3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jacep.2021.01.022","article-title":"Incidence and predictors of sudden cardiac arrest in sarcoidosis: a nationwide analysis","volume":"7","author":"Narasimhan","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2025091923515252000_108.6.429.4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijcard.2020.11.044","article-title":"Risk and predictors of sudden death in cardiac sarcoidosis: a systematic review and meta-analysis","volume":"328","author":"Franke","year":"2021","journal-title":"Int J Cardiol"},{"key":"2025091923515252000_108.6.429.5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1111\/jce.14058","article-title":"Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function","volume":"30","author":"Zipse","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2025091923515252000_108.6.429.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"2025091923515252000_108.6.429.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.851352"},{"key":"2025091923515252000_108.6.429.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2017.09.175"},{"key":"2025091923515252000_108.6.429.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq178"},{"key":"2025091923515252000_108.6.429.10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2015.04.144","article-title":"Urinary 8-hydroxy-2\u2032-deoxyguanosine as a novel biomarker of inflammatory activity in patients with cardiac sarcoidosis","volume":"190","author":"Kobayashi","year":"2015","journal-title":"Int J Cardiol"},{"key":"2025091923515252000_108.6.429.11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijcard.2016.03.003","article-title":"An oxidative stress biomarker, urinary 8-hydroxy-2\u2032-deoxyguanosine, predicts cardiovascular-related death after steroid therapy for patients with active cardiac sarcoidosis","volume":"212","author":"Myoren","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025091923515252000_108.6.429.12","article-title":"Urinary 8-hydroxy-2\u2032-deoxyguanosine as a myocardial oxidative stress marker is associated with ventricular tachycardia in patients with active cardiac sarcoidosis","volume":"10","author":"Ishiguchi","year":"2017","journal-title":"Circulation"},{"key":"2025091923515252000_108.6.429.13","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis \u2015 Digest Version \u2015","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"2025091923515252000_108.6.429.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.03.043"},{"key":"2025091923515252000_108.6.429.15","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1253\/circj.CJ-19-0248","article-title":"Detection of active inflammation status around ventricular aneurysms in patients with cardiac sarcoidosis","volume":"83","author":"Nanno","year":"2019","journal-title":"Circ J"},{"key":"2025091923515252000_108.6.429.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.304555"},{"key":"2025091923515252000_108.6.429.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv316"},{"key":"2025091923515252000_108.6.429.18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.hroo.2021.07.005","article-title":"Management of ventricular tachycardia in patients with cardiac sarcoidosis","volume":"2","author":"Viwe","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"2025091923515252000_108.6.429.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163250","article-title":"Recombinant atrial natriuretic peptide prevents aberrant Ca2+ leakage through the ryanodine receptor by suppressing mitochondrial reactive oxygen species production induced by isoproterenol in failing cardiomyocytes","volume":"11","author":"Murakami","year":"2016","journal-title":"PLoS One"},{"key":"2025091923515252000_108.6.429.20","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2012.230748"},{"key":"2025091923515252000_108.6.429.21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00734.2013"},{"key":"2025091923515252000_108.6.429.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.555623"},{"key":"2025091923515252000_108.6.429.23","unstructured":"Anderson ME , Hodgson-Zingman DM . Ventricular tachycardia in patients with heart failure. In: Zipes DP , Jalife J , eds. Cardiac electrophysiology: from cell to bedside. fifth edition. WB Sauders, 2009: 707\u201316."},{"key":"2025091923515252000_108.6.429.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2010.03.013"},{"key":"2025091923515252000_108.6.429.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.114.002145"},{"key":"2025091923515252000_108.6.429.26","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(72)90073-2"},{"key":"2025091923515252000_108.6.429.27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijcard.2014.10.024","article-title":"Presence of ventricular aneurysm predicts poor clinical outcomes in patients with cardiac sarcoidosis","volume":"177","author":"Miyazawa","year":"2014","journal-title":"Int J Cardiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2021-320244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:51:59Z","timestamp":1758351119000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2021-320244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,2,24]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/heartjnl-2021-320244"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2021-320244","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}